India · Delayed Price · Currency is INR Praj Industries Earnings Call Transcripts
Fiscal Year 2026
-
Q4 and FY 2026 saw lower profits due to execution delays, cost escalations, and raw material volatility, but strong order backlog and new mandates in bioenergy and data centers support a positive FY 2027 outlook. R&D and international opportunities remain key growth drivers.
-
Steady operational performance was maintained despite margin pressures from export mix and project execution. Large orders in Engineering and new technology commercialization in BioEnergy and CBG are set to drive future growth, with margin improvement expected as facility utilization rises.
-
Q2 and H1 FY26 saw strong execution amid headwinds, with revenue growth driven by international bioenergy and engineering segments. Project delays due to funding challenges and U.S. tariffs impacted margins, but a diversified portfolio and new technology initiatives support long-term growth.
-
Q1-FY26 saw a sharp decline in revenue and profit due to lower volumes, delayed execution, and higher costs, though order intake remained robust. Management expects margin recovery from H2, with growth focused on ethanol, CBG, and international markets.
Fiscal Year 2025
-
Revenue and profit declined YoY due to execution delays and higher site expenses, but margins improved sequentially. Strong order backlog, international growth, and new technology launches position the business for future expansion, with Genex and CBG segments set to drive growth.
-
Order book hit a three-quarter high with strong international growth and a 40% overseas share. Q3 revenue rose slightly YoY, but margins and profit declined due to sales mix and GenX facility delays. Management maintains ambitious 2030 growth targets and expects SAF and CBG markets to drive future expansion.
-
Q2 FY25 saw lower revenue and profit YoY, but order intake and backlog remain strong, especially in bioenergy and services. The company is capitalizing on global biofuel demand, new biopolymer capabilities, and expects margin stability and revenue growth in coming quarters.
-
Q1 FY25 saw strong international growth and margin improvement, despite a domestic slowdown due to feedstock policy uncertainty. Major advances included new biopolymer technology, robust export orders, and a healthy order backlog, with management optimistic for improved order booking and revenue ramp-up in the coming quarters.